Antengene Secures Clinical Trial Approval in Australia for Innovative ATG-201 Study
Antengene Corporation has received approval for a Phase I clinical trial of ATG-201, a novel treatment targeting B cell-related autoimmune diseases. This significant step marks a potential breakthrough in the management of these complex conditions.